

Accepted Manuscript

Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial

Edward Kerwin, Andrew Wachtel, Lawrence Sher, Jack Nyberg, Patrick Darken, Shahid Siddiqui, Elizabeth A. Duncan, Colin Reisner, Paul Dorinsky

PII: S0954-6111(18)30121-5

DOI: [10.1016/j.rmed.2018.04.013](https://doi.org/10.1016/j.rmed.2018.04.013)

Reference: YRMED 5428

To appear in: *Respiratory Medicine*

Received Date: 21 February 2018

Accepted Date: 18 April 2018

Please cite this article as: Kerwin E, Wachtel A, Sher L, Nyberg J, Darken P, Siddiqui S, Duncan EA, Reisner C, Dorinsky P, Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial, *Respiratory Medicine* (2018), doi: 10.1016/j.rmed.2018.04.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: a randomized controlled trial

Edward Kerwin^{a,*}, Andrew Wachtel^b, Lawrence Sher^c, Jack Nyberg^d, Patrick Darken^d, Shahid Siddiqui^e, Elizabeth A. Duncan^f, Colin Reisner^{d,e}, Paul Dorinsky^f

^a*Clinical Research Institute of Southern Oregon, Medford, OR, USA*

^b*Southern California Institute for Respiratory Diseases, Los Angeles, CA, USA*

^c*Peninsula Research Associates, Rolling Hills Estates, CA, USA*

^d*Pearl – a member of the AstraZeneca Group, Morristown, NJ, USA*

^e*AstraZeneca, Gaithersburg, MD, USA*

^f*Pearl – a member of the AstraZeneca Group, Durham, NC, USA*

***Corresponding author:** Clinical Research Institute of Southern Oregon, 3860 Crater Lake Avenue, Medford, Oregon 97504, USA. Tel. +1 541 858 1003

E-mail address: ekerwin@criresearch.com (Edward Kerwin)

Download English Version:

<https://daneshyari.com/en/article/8819891>

Download Persian Version:

<https://daneshyari.com/article/8819891>

[Daneshyari.com](https://daneshyari.com)